Exploring the role of serotonin in oculocutaneous albinism
Official title: Role of Peripheral Serotonin in Oculocutaneous Albinism
Run by Assistance Publique - Hôpitaux de Paris · NCT06138509 · Data updated 2026-11-12
This study is trying to see how serotonin levels in the blood affect skin and eye color in kids and teens with oculocutaneous albinism.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years to 17 Years |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | February 6, 2024 |
| Main results expected | February 2026 |
| Study ends | February 2026 |
| Registry record updated | September 12, 2025 |
| Trial ID | NCT06138509 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients aged 2 to 17 years diagnosed with oculocutaneous albinism.
✕Probably not a fit
Patients who are unable to undergo blood tests or have abnormal blood counts will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the relationship between peripheral serotonin levels and oculocutaneous albinism in patients aged 2 to 17 years. It aims to assess blood parameters and serotonin metabolites to understand their potential impact on pigmentation and iron metabolism. The study will involve patients with albinism and a control group from the Necker hospital, focusing on the clinical and genetic heterogeneity of albinism. By examining these factors, the research seeks to address significant unmet clinical needs in this population.
Why it matters
Potential benefit: If successful, this study could lead to a better understanding of the role of serotonin in pigmentation and iron metabolism, potentially informing future treatments for patients with albinism.
How similar studies have gone: While the role of serotonin in pigmentation is being explored, this specific approach in the context of oculocutaneous albinism is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients: * Patients with albinism aged 2 to 17 years * Followed in the MAGEC-Necker reference center (reference center for rare diseases of the skin and mucous membranes of genetic origin), during the inclusion period * Information of parental authority holders of patients and patients of understanding age, and collection of consent from parental authority holders and patients. Controls: * Patients aged 2 to 17 years old * Having consulted in Necker hospital during the inclusion period in the emergency and surgical services and whose care required a blood test analyzed in the hematology laboratory of the Necker hospital. * Normal complete blood count (CBC) * Normal C-reactive protein test (CRP) * Absence of opposition from parental authority holders within one month of after sending the study information note. Exclusion Criteria: Patients: \- Inability to have a blood test Controls: * Abnormal blood count * Elevation of CRP above laboratory standard
Where it's running
-
Hôpital Necker-Enfants Malades
Paris, France Recruiting
Study contacts
- Principal investigator: Smail HADJ-RABIA, MD, PhD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Smail HADJ-RABIA, MD, PhD
- Email: smail.hadjrabia@aphp.fr
- Phone: 1 44 49 46 62
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Single suprachoroidal JWK010 gene therapy injection for children with OCA1A
This trial will try a single suprachoroidal injection of JWK010 gene therapy in children aged 5–12 with TYR-related OCA1A to see if it restores retinal pigment and improves vision.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.